FORA Capital LLC Has $1.07 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

FORA Capital LLC grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 38.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 14,818 shares of the medical equipment provider’s stock after buying an additional 4,088 shares during the quarter. FORA Capital LLC’s holdings in Hologic were worth $1,068,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in HOLX. Geode Capital Management LLC raised its position in shares of Hologic by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock valued at $412,159,000 after purchasing an additional 144,838 shares during the period. Victory Capital Management Inc. grew its position in shares of Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock valued at $354,506,000 after purchasing an additional 24,358 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock worth $322,272,000 after purchasing an additional 129,035 shares during the period. Invesco Ltd. lifted its position in shares of Hologic by 16.4% during the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock worth $293,434,000 after purchasing an additional 572,187 shares during the last quarter. Finally, Boston Partners grew its holdings in Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after buying an additional 1,602,463 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Activity

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the company’s stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director now directly owns 5,445 shares of the company’s stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 1.88% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Raymond James reissued an “outperform” rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Friday, May 2nd. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Finally, Royal Bank of Canada decreased their target price on Hologic from $75.00 to $70.00 and set a “sector perform” rating on the stock in a research report on Friday, May 2nd. Twelve analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $78.58.

Hologic Price Performance

Shares of HOLX stock opened at $56.74 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock’s fifty day simple moving average is $59.43 and its 200 day simple moving average is $68.34. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The firm has a market cap of $12.73 billion, a price-to-earnings ratio of 17.90, a P/E/G ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.03 EPS. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.